Editorial commentary on "Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo".
作者信息
Yamanishi Tomonori, Kamasasko Tomohiko, Kaga Kanya, Fuse Miki
机构信息
Department of Urology, Continence Center, Dokkyo Medical University, Tochigi, Japan.
出版信息
Transl Androl Urol. 2020 Jun;9(3):1009-1012. doi: 10.21037/tau-2020-02.
Abstract
摘要
相似文献
1
Editorial commentary on "Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo".关于“米拉贝隆的安全性和有效性：对接受米拉贝隆、抗毒蕈碱药物或安慰剂治疗的膀胱过度活动症患者大型综合临床试验数据库的分析”的编辑评论
Transl Androl Urol. 2020 Jun;9(3):1009-1012. doi: 10.21037/tau-2020-02.
2
Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo.评论：米拉贝隆的安全性和有效性：对接受米拉贝隆、抗毒蕈碱药物或安慰剂的膀胱过度活动症患者的大型综合临床试验数据库的分析。
Transl Androl Urol. 2020 Oct;9(5):2305-2307. doi: 10.21037/tau-20-876.
3
Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome.米拉贝隆的心血管安全性：膀胱过度活动症患者综合临床试验数据库分析
J Am Soc Hypertens. 2018 Nov;12(11):768-778.e1. doi: 10.1016/j.jash.2018.08.001. Epub 2018 Aug 10.
4
Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.医学治疗过度活跃膀胱的疗效和安全性比较：系统文献回顾和混合治疗比较。
Eur Urol. 2014 Apr;65(4):755-65. doi: 10.1016/j.eururo.2013.11.010. Epub 2013 Nov 18.
5
Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.老年患者膀胱过度活动症的口服药物治疗：米拉贝隆作为抗毒蕈碱药物的潜在替代药物
Curr Med Res Opin. 2016;32(4):621-38. doi: 10.1185/03007995.2016.1149806. Epub 2016 Feb 17.
6
Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.米拉贝隆治疗膀胱过度活动症：疗效、安全性及耐受性综述，重点关注男性、老年及抗毒蕈碱反应不佳人群以及亚洲膀胱过度活动症患者
Expert Rev Clin Pharmacol. 2017 Feb;10(2):131-151. doi: 10.1080/17512433.2017.1275570. Epub 2017 Jan 16.
7
Evidence available on the use of the selective β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder.关于使用选择性β3肾上腺素能受体激动剂米拉贝隆治疗膀胱过度活动症的现有证据。
Actas Urol Esp. 2013 Nov-Dec;37(10):640-51. doi: 10.1016/j.acuro.2013.05.003. Epub 2013 Jul 12.
8
A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain.一项回顾性研究，比较米拉贝隆与抗毒蕈碱药物治疗西班牙膀胱过度活动症的治疗持久性和依从性。
BMC Urol. 2018 Sep 4;18(1):76. doi: 10.1186/s12894-018-0390-z.
9
Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.米拉贝隆对比抗胆碱能单药治疗或联合治疗用于治疗膀胱过度活动症的疗效和耐受性：一项系统评价和网络荟萃分析。
Eur Urol. 2018 Sep;74(3):324-333. doi: 10.1016/j.eururo.2018.03.020. Epub 2018 Apr 23.
10
Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.米拉贝隆与抗胆碱能药物治疗膀胱过度活动症患者的坚持和依从性：英国临床实践中的回顾性观察研究。
Eur Urol. 2017 Sep;72(3):389-399. doi: 10.1016/j.eururo.2017.01.037. Epub 2017 Feb 11.
引用本文的文献
1
Vibegron for overactive bladder in men with benign prostatic hyperplasia/obstruction: insights from the COURAGE trial.维贝格隆用于良性前列腺增生/梗阻男性的膀胱过度活动症：来自COURAGE试验的见解
Transl Androl Urol. 2025 Apr 30;14(4):888-892. doi: 10.21037/tau-2024-759. Epub 2025 Apr 10.
本文引用的文献
1
Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.米拉贝隆的安全性和疗效：接受米拉贝隆、抗毒蕈碱药物或安慰剂的膀胱过度活动症患者大型综合临床试验数据库分析。
Eur Urol. 2020 Jan;77(1):119-128. doi: 10.1016/j.eururo.2019.09.024. Epub 2019 Oct 18.
2
Efficacy of novel β -adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study.新型β-肾上腺素能受体激动剂维贝格隆治疗膀胱过度活动症患者夜尿症的疗效：一项随机、双盲、安慰剂对照的 3 期研究的事后分析。
Int J Urol. 2019 Mar;26(3):369-375. doi: 10.1111/iju.13877. Epub 2018 Dec 17.
3
Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost-effective as the first-line treatment?米拉贝隆或托特罗定用于日本膀胱过度活动症的治疗：哪种药物作为一线治疗更具成本效益？
Int J Urol. 2018 Oct;25(10):863-870. doi: 10.1111/iju.13764. Epub 2018 Aug 15.
4
Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE).接受米拉贝隆联合索利那新治疗的难治性膀胱过度活动症失禁患者的心血管安全性（BESIDE研究）
Int J Clin Pract. 2017 May;71(5). doi: 10.1111/ijcp.12944. Epub 2017 Apr 16.
5
Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).米拉贝隆与索利那新联合用药对比单药治疗及安慰剂治疗对膀胱过度活动症患者的疗效和安全性（协同研究）
BJU Int. 2017 Oct;120(4):562-575. doi: 10.1111/bju.13882. Epub 2017 Jun 8.
6
Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.米拉贝隆与抗胆碱能药物治疗膀胱过度活动症患者的坚持和依从性：英国临床实践中的回顾性观察研究。
Eur Urol. 2017 Sep;72(3):389-399. doi: 10.1016/j.eururo.2017.01.037. Epub 2017 Feb 11.
7
The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial.与索利那新相比，米拉贝隆对因疗效不佳而对先前抗毒蕈碱治疗不满意的膀胱过度活动症患者的疗效和安全性：一项非劣效性、随机、IIIb期试验的结果
Ther Adv Urol. 2015 Aug;7(4):167-79. doi: 10.1177/1756287215589250.
8
Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).米拉贝隆与索利那新联合治疗膀胱过度活动症患者的疗效和安全性：一项随机、双盲、剂量范围、2 期研究（Symphony）的结果。
Eur Urol. 2015 Mar;67(3):577-88. doi: 10.1016/j.eururo.2014.02.012. Epub 2014 Feb 19.
9
A phase II dose-ranging study of mirabegron in patients with overactive bladder.米拉贝隆用于膀胱过度活动症患者的II期剂量范围研究。
Int Urogynecol J. 2013 Sep;24(9):1447-58. doi: 10.1007/s00192-013-2042-x. Epub 2013 Mar 8.
10
Efficacy of extended-release tolterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder.延长释放托特罗定治疗神经原性逼尿肌过度活动症和/或顺应性膀胱不良的疗效。
Int J Urol. 2010 Nov;17(11):931-6. doi: 10.1111/j.1442-2042.2010.02635.x. Epub 2010 Oct 4.
Zotero 插件